A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Therapeutics
Chimeric Therapeutics
Tanabe Pharma America, Inc.
PharmaMar
Cancer Research UK
Hutchmed
Aminex Therapeutics, Inc.
Institut Bergonié